English 
Japanese 
TOKYO, Japan, 24 Jan 2024: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced a 1.5 billion yen ($10.3M) fundraise. Funds will be used to refine PRISM’s proprietary PepMetics® chemistry platform, expand biology and screening capabilities and advance internal pipeline of...
Archives: News
PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target
TOKYO, Japan, 28 Nov 2023: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company. Read Full Press Release
Rational Strategy for Designing Peptidomimetic Small Molecules Based on Cyclic Peptides Targeting Protein–Protein Interaction between CTLA-4 and B7-1
Pharmaceuticals 2022, 15(12), 1506
Tsuihiji, Kumiko; Honda, Eiji; Kojoh, Kanehisa; Katoh, Shizue; Taguri, Tomonori; Yoshimori, Atsushi; Takashima, Hajime
Development of low-molecular-weight compounds targeting the cancer-associated KLF5 transcription factor
ACS Medicinal Chemistry Letters, 13(4), 687-694 (2022)
Nakaya, Takeo; Aizawa, Kenichi; Taguchi, Yuki; Tsuji, Kentaro; Sekine, Sachi; Murakami, Kazuhiro; Kasai, Masaji; Nakano, Hirofumi; Kondoh, Yasumitsu; Dan, Shingo; Yoshimori, Atsushi; Kouji, Hiroyuki; Takehara, Dai; Suzuki, Toru; Osada, Hiroyuki; Marata, Masayuki; Tanaka, Akira; Nagai, Ryozo
PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical
TOKYO, Japan, 31 May 2023: – PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced a milestone achievement of a clinical development conducted by Ohara Pharmaceutical Co., Ltd., a Japanese pharmaceutical company that discovers and develops orphan drugs and generic drugs, based on their licensing...
New study by PRISM Biolab demonstrates rational design of small molecule inhibitors of CTLA-4 and B7-1 protein-protein interaction utilizing only a sequence of a binding peptide
The paper published in the special issue of Pharmaceuticals journal dedicated to “Small Molecules Targeting Protein-Protein Interactions (PPIs): Current Strategies for the Development of New Drugs” presents a new method to generate small-molecules PPI inhibitors using only a sequence of a binding peptide. Potent and active PPI inhibitor peptides can be readily generated by various...
Pharma Intelligence Award Japan 2022 Commemorative Webinar “PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm”
PRISM BioLab’s proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein interactions by small molecules with a unique peptide-mimicking backbone, potentially creating a new drug discovery paradigm. In this webinar, Dai Takehara, President of PRISM BioLab, will introduce the PepMetics® technology and share his experiences in managing a biotech startup,...
PRISM Biolab Wins Biotech Company of the Year Award of Informa Pharma Intelligence Award 2022
We are pleased to announce that we have won the Biotech company of the year in the Private category of the Informa Pharma Intelligence Award 2022, the Japanese version of the Scrip Awards, which have been held in the UK for 17 years. Read More | Event Report
PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech
TOKYO, Japan, 5th Jan. 2022: — PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multitarget research collaboration and licensing agreement with Roche and Genentech, a member of the Roche Group. Read Full Press Release
The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) / β-catenin inhibitor E7386, a medium-molecular weight compound created through collaboration research between Eisai and PRISM, has achieved the clinical POC (Proof of Concept). Read Full Press Release